I just watched this interview in Turkish and it has been mistranslated. Dr. Sahin says they do expect 70-75% protection against symptomatic illness for B.1.617.2 variant, but he does NOT say "up to". He says it's not a hard number as they're still testing and will know more soon.https://twitter.com/GabrielScally/status/1395697659953008643 …
-
Show this thread
-
Replying to @zeynep
I just watched it as well, it’s been translated incorrectly. He says ‘around’ not ‘up to’. Plus this vaccine showed 75% protection against infection vs b1.315 in Qatar. So, effectiveness will be much higher against b1.617.2 as there is less reduction in nAb response w/ b1.617.2.
10 replies 17 retweets 202 likes -
Replying to @mugecevik @zeynep
Has there now been in vitro lab data to demonstrate this? I've seen quite a few studies for B.1.617.1 but data on .2 is thin on the ground.
1 reply 0 retweets 11 likes -
Not live virus data but pseudovirus neutralisation assay w/ mutations seen in .2.
6 replies 0 retweets 22 likes -
Pseudovirus neutralisation assays are only moderately informative and the data I've seen seemed more relevant for B.1.617.1. That said, it would be surprised if vaccine efficacy were lower than against B.1.351.
5 replies 0 retweets 41 likes
He was being pressed by the minister and made it clear he wasn’t yet in a position to provide a precise estimate. Also I wish the difference between symptomatic breakthroughs after vaccination and cases in immunologically naive people were explained more clearly, in general.
Loading seems to be taking a while.
Twitter may be over capacity or experiencing a momentary hiccup. Try again or visit Twitter Status for more information.